RxDoctor Payments Data

Ashesh Buch, MD

Interventional Cardiology · Chesapeake, VANPI 1114287117

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,550 of the $14,115 with a category attached, or 60.6%. 22 manufacturers reported payments, led by Cardiovascular Systems Inc. at 34.3% of the total. Reporting peaked in 2022 at $5,813 and has fallen 96.3% since, to $216 in 2025.

$14,115in general payments, 2019–2025

Across 97 payments — averaging $145.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$5K
  • Abbott$5K
  • Philips North America LLC$3K
  • Boston Scientific$234
  • Shockwave Medical, Inc$179
  • Abiomed$175
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$8,55061%
  • Travel & lodging$2,25616%
  • Food & beverage$3,16122%
  • Education$1481%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,115 in reported general payments places this provider in the 75th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$89,092
Medicare patients
515
Services billed
1,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$76,609
XareltoRivaroxaban42$40,073
EntrestoSacubitril/Valsartan29$36,490
BrilintaTicagrelor15$9,998
Dabigatran EtexilateDabigatran Etexilate Mesylate13$2,140
Metoprolol Succinate131$1,643
Atorvastatin Calcium149$1,298
Bumetanide30$689
Bisoprolol Fumarate23$665
ClopidogrelClopidogrel Bisulfate38$576
Rosuvastatin Calcium36$540
Chlorthalidone38$538
Spironolactone58$509
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$450
Valsartan17$450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$76,60972 claims
Johnson & JohnsonXarelto$80$40,07342 claims
NovartisEntresto$96$36,49029 claims
AstraZenecaBrilinta$135$9,99815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →